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Table 1. Comparison of patients characteristics between both groups
Variable
Hypo-responders
N=15 (68%)
Responders
N=7 (32%) P value
Age (years) 84.17.4 76.817 0.08
Gender (Men) 11 (73%) 2 (29%) 0.07
Body Mass Index 30.15.9 24.25.4 0.01
HTN 15 (100%) 7 (100%) 1
DM 8 (40%) 6 (86%) 0.19
Dyslipidemia 14 (93%) 3 (43%) 0.02
Prior Smoker 8 (53%) 3 (43%) 0.9
Prior MI 4 (27%) 2 (29%) 1
Admission with
CHF
14 (93%) 6 (86%) 0.9
Troponin I (ng/ml) 3.68  3.13 0.05  0.04 0.04
Cholesterol (mg/dl) 117.7  15.7 88.5  14.8 0.03
Hg (g/dl) 9.87  1.4 9.57  1.6 0.3
PLT (K/ul) 159  43.9 172  68.9 0.3
Creatinine (mg/dl) 1.75  1.9 1.73 1.6 0.5
HTN- Hypertension; DM- Diabetes Mellitus; MI- Myocardial infarction; CHF- Congestive heart
failure; CK- Creatine kinase; Hg- hemoglobin; PLT- platelets
TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM www.jacctctabstracts2013.com
P
O
S
T
E
R
SConclusions: Clopidogrel hypo-responsiveness post TAVR is a very common
phenomenon. These patients are characterized by higher BMI, dyslipidemia and
a trend towards older age and male gender. MACE rate at 30 days was similar for
responders and hypo-responders. Further studies are needed to investigate this high
rate of hypo-responsiveness post TAVR and its potential consequences on clinical
outcomes.
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Background: Coronary artery disease (CAD) and aortic stenosis (AS) frequently
coexist. It remains unknown whether CAD severity exerts a gradient of risk in patients
with AS undergoing transcatheter aortic valve implantation (TAVI).
Methods: A total of 445 patients with severe AS undergoing TAVI were included into
a prospective registry between 2007 and 2012. The preoperative SYNTAX-score (SS)
was determined from baseline coronary angiograms. In case of revascularization prior
to TAVI, residual SS (rSS) was also determined. Clinical outcomes were compared
between patients without CAD (N¼158), patients with low SS (0-22, N¼207), and
patients with high SS (SS>22, N¼80). The prespeciﬁed primary endpoint was the
composite of cardiovascular death, stroke, or myocardial infarction (MI).
Results: At one year, CAD severity was associated with higher rates of the primary
endpoint (noCAD: 12.5%, low SS: 16.1%, high SS: 29.6%; p¼0.016). This was driven by
differences in cardiovascular death (no CAD: 8.6%, low SS: 13.6%, high SS: 20.4%;
p¼0.029), whereas the risk of stroke (no CAD: 5.1%, low SS: 3.3%, high SS: 6.7%;
p¼0.79) andMI (noCAD:1.5%, lowSS: 1.1%, highSS: 4.0%; p¼0.54)was similar across
the threegroups.Patientswith highSS received less complete revascularization as indicated
by a higher rSS (21.212.0vs. 4.04.4, p<0.001) comparedwith patientswith lowSS.Of
note, the highest rSS tertile (rSS>14) was associated with higher rates of the primary
endpoint at 1 year (no CAD: 12.5%, low rSS: 16.5%, high rSS: 26.3%, p¼0.043).
Conclusions: CAD is present in two-thirds of elderly patients with severe AS
undergoing TAVI in routine clinical practice. Severity of CAD appears to be asso-
ciated with impaired clinical outcomes at 1 year after TAVI. Patients with SS>22
receive less complete revascularization and have a higher risk of cardiovascular death,
stroke, or MI as compared to patients without CAD or low SS.
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Background: Right ventricular (RV) function is reduced after surgical aortic valve
replacement (sAVR). The long-term effect on RV function following transcatheterB222 JACC Vol 62/18/Suppl B j October 27–Novemberaortic valve implantation (TAVI) is less well established. The aim of this study was to
determine whether TAVI may preserve RV function at medium-term outcome.
Methods: We studied 79 consecutive patients (aged 837 years) with severe AS but
no ﬂow-limiting coronary artery disease, one week before and 12 months after
transfemoral TAVI with CoreValve. The TAVI group was compared with 36 patients
(aged 703 years) who underwent sAVR for severe aortic stenosis (AS). RV inlet
diameter measurement was averaged from apical 4-chamber and modiﬁed parasternal
windows, and tricuspid annular plain systolic excursion (TAPSE) was measured as the
M-mode displacement of the tricuspid ring between the q wave of the ECG to
pulmonary valve closure.
Results: The sAVR and TAVI groups had similar AS severity pre-operatively (mean
aortic pressure drop 5117mmHg vs. 4915mmHg respectively, and valve area
0.7cm2 vs 0.6cm2, p¼NS for both), though LVEF was reduced in TAVI patients
(657% vs. 4916%, p<0.001). There was no difference in RV size (353mm vs.
336mm), though TAPSE was greater in sAVR group (205mm vs. 156mm,
p<0.001). At 12 months, mean aortic pressure drop decreased and aortic valve area
increased in both sAVR and TAVI (to 103mmHg and 82mmHg respectively, and
to 2.00.3cm2 vs. 1.80.2cm2, p<0.01 for both), though LVEF did not change
(629% vs. 4917%). Although RV cavity size did not change in either group,
TAPSE decreased after sAVR (to 93mm) and increased after TAVI (174mm,
difference p<0.001).
Conclusions: At medium-term follow-up, RV function deteriorates after sAVR but
does not worsen after transfemoral TAVI. Therefore, patients with AS and pre-
existing RV dysfunction may beneﬁt preferentially from TAVI. Though clinical
signiﬁcance remains to be determined, RV function should be incorporated into risk
score pre-procedure.
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Background: Gait speed (GS) is an independent predictor of mortality after cardiac
surgery, however association with clinical outcomes in patients with severe aortic
stenosis (AS) undergoing surgical aortic valve replacement (SAVR) versus trans-
catheter AVR (TAVR) are limited.
Methods: From 3/2011-12/2012, all patients with severe AS evaluated by a multi-
disciplinary heart team underwent standardized GS testing with the 5 meter walk test.
Operative outcomes were assessed based on GS as both a continuous (m/s) and
categorical (normal/slow) variable with immobile patients assigned a GS of 0 m/s. The
primary end points were 30 day and one year mortality.
Results: We enrolled 285 patients (SAVR¼76, TAVR¼209). The optimal cutoff to
discriminate slow from normal GS was 0.7 m/s (6.9s/5m). Patients with normal GS
had a higher survival at one year(Figure). Overall normal GS was an independent
predictor of mortality at 30 days (OR 0.31,95% CI 0.11-0.88;p¼0.028) and one year
(OR 0.34 ,95% CI 0.12-0.99;p¼0.048) with an 11% reduction in 30 day mortality for
every 0.1m/s increase in walk speed. For one year mortality the STS PROM had an
AUC¼0.681, increasing to 0.704 with GS added. GS was an independent predictor of
30 day mortality after TAVR but not SAVR; with no signiﬁcant association with
mortality in the individual groups at one year.
Conclusions: GS is an independent predictor of mortality in patients with severe AS
undergoing therapy including TAVR, but adds minimal additional predictive infor-
mation to the STS risk score. Patients with slow GS or immobility should be carefully
evaluated and counseled regarding mortality risk.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
